Literature DB >> 11193832

VPAC1 receptors and lung cancer.

T W Moody1, J Walters, M Casibang, F Zia, Y Gozes.   

Abstract

VIP/PACAP are autocrine growth factors for lung cancer. VIP and/or PACAP mRNA is present in most lung cancer cell lines examined. Although mRNA for VPAC2-R is not common, VPAC1-R and PAC1-R mRNA is present in many lung cancer cell lines. 125I-VIP binds with high affinity to lung cancer cells and specific 125I-VIP binding is inhibited with high affinity by (Lys15, Arg16, Leu27)VIP1-7 GRF8-27, the VPAC1-R specific agonist, but not by Ro25-1553(18), the VPAC2-R specific agonist. VIP elevates cAMP and increases c-fos gene expression. The increase in cAMP and c-fos mRNA caused by VIP is inhibited by SN(VH). (SH)VH inhibited the proliferation of NCIH1299 cells in the MTT assay, which is based on cytotoxicity. In a recent cell line screen, (SN)VH inhibited the growth of 51 of 56 cancer cell lines including leukemia, lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, breast cancer, and prostate cancer (T. Moody, unpublished). It remains to be determined if (SN)VH will be useful for treatment of a wide variety of cancers.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11193832      PMCID： PMC8820160          DOI： 10.1111/j.1749-6632.2000.tb06947.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  21 in total

1.  Characterization of VIP- and helodermin-preferring receptors on human small cell lung carcinoma cell lines.

Authors:  J Luis; S I Said
Journal:  Peptides       Date:  1990 Nov-Dec       Impact factor: 3.750

2.  Secretin/vasoactive intestinal peptide-stimulated secretion of bombesin/gastrin releasing peptide from human small cell carcinoma of the lung.

Authors:  L Y Korman; D N Carney; M L Citron; T W Moody
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

3.  (Arg15, Arg21) VIP: evaluation of biological activity and localization to breast cancer tumors.

Authors:  T W Moody; J Leyton; E Unsworth; C John; L Lang; W C Eckelman
Journal:  Peptides       Date:  1998       Impact factor: 3.750

Review 4.  Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways.

Authors:  A J Whitmarsh; R J Davis
Journal:  J Mol Med (Berl)       Date:  1996-10       Impact factor: 4.599

5.  [Psi 13,14] bombesin analogues inhibit growth of small cell lung cancerin vitro and in vivo.

Authors:  S Mahmoud; J Staley; J Taylor; A Bogden; J P Moreau; D Coy; I Avis; F Cuttitta; J L Mulshine; T W Moody
Journal:  Cancer Res       Date:  1991-04-01       Impact factor: 12.701

6.  Response of primary human lung carcinomas to autocrine growth factors produced by a lung carcinoma cell line.

Authors:  J M Siegfried; S E Owens
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

7.  Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.

Authors:  I Virgolini; M Raderer; A Kurtaran; P Angelberger; S Banyai; Q Yang; S Li; M Banyai; J Pidlich; B Niederle; W Scheithauer; P Valent
Journal:  N Engl J Med       Date:  1994-10-27       Impact factor: 91.245

8.  A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

Authors:  T W Moody; F Zia; M Draoui; D E Brenneman; M Fridkin; A Davidson; I Gozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

9.  Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.

Authors:  Y Nakanishi; J L Mulshine; P G Kasprzyk; R B Natale; R Maneckjee; I Avis; A M Treston; A F Gazdar; J D Minna; F Cuttitta
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

10.  BW2258U89: a GRP receptor antagonist which inhibits small cell lung cancer growth.

Authors:  T W Moody; R Venugopal; F Zia; S Patierno; J J Leban; J McDermed
Journal:  Life Sci       Date:  1995       Impact factor: 5.037
View more
  9 in total

1.  PACAP immunoreactivity in human malignant tumor samples and cardiac diseases.

Authors:  Z Szanto; Zs Sarszegi; D Reglodi; J Nemeth; K Szabadfi; P Kiss; A Varga; E Banki; K Csanaky; B Gaszner; O Pinter; Zs Szalai; A Tamas
Journal:  J Mol Neurosci       Date:  2012-05-31       Impact factor: 3.444

2.  VIP, from gene to behavior and back: summarizing my 25 years of research.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

3.  Vasoactive intestinal peptide signaling axis in human leukemia.

Authors:  Glenn Paul Dorsam; Keith Benton; Jarrett Failing; Sandeep Batra
Journal:  World J Biol Chem       Date:  2011-06-26

Review 4.  Peptide receptors as cancer drug targets.

Authors:  Terry W Moody
Journal:  Ann N Y Acad Sci       Date:  2019-05-10       Impact factor: 5.691

Review 5.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

6.  PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells.

Authors:  Terry W Moody; Julius Leyton; Marchessini Casibang; Joseph Pisegna; Robert T Jensen
Journal:  Regul Pept       Date:  2002-11-15

Review 7.  Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide [Part 1]: biology, pharmacology, and new insights into their cellular basis of action/signaling which are providing new therapeutic targets.

Authors:  Terry W Moody; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2021-04-01       Impact factor: 3.626

Review 8.  Anticipated pharmacological role of Aviptadil on COVID-19.

Authors:  Tuhin Mukherjee; Tapan Behl; Sanchay Sharma; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Bijo Mathew; Jasleen Kaur; Ratandeep Kaur; Mayukh Das; Lotfi Aleya; Simona Bungau
Journal:  Environ Sci Pollut Res Int       Date:  2021-11-30       Impact factor: 5.190

9.  Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER.

Authors:  Véronique Gigoux; Daniel Fourmy
Journal:  Front Endocrinol (Lausanne)       Date:  2013-04-29       Impact factor: 5.555
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.